Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
50%
Breast Cancer
40%
Early Breast Cancer
27%
Overall Survival
27%
Chemotherapy
26%
Confidence Interval
19%
Graft-versus-host Disease (GvHD)
18%
Hazard Ratio
17%
Non-relapse Mortality
16%
BRCA1, BRCA2
15%
Acute Myeloid Leukemia
14%
Breast Cancer Patients
14%
Fludarabine
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Phase II Trial
13%
Disease-free Survival
12%
Trastuzumab
12%
Triple-negative Breast Cancer
11%
Advanced Breast Cancer
11%
Reduced-intensity Conditioning
11%
High Risk
11%
Oncotype DX
11%
Progression-free Survival
11%
BRCA Carriers
10%
Meta-analysis
10%
Stem Cell Transplantation
10%
Recurrence Score
10%
BRCA mutation Carriers
10%
Relapsed or Refractory
9%
BRCA mutation
9%
Unrelated Donor
9%
Estrogen Receptor-positive
9%
Chimeric Antigen Receptor T-cell Therapy
9%
Tumor
9%
Chimeric Antigen Receptor T Cells (CAR-T)
8%
Metastatic Breast Cancer
8%
Non-Hodgkin Lymphoma
8%
Hormone Receptor-positive
8%
Transplantation
8%
Breast Cancer Subtypes
8%
Multivariate Analysis
8%
Granulocyte Colony-stimulating Factor (G-CSF)
8%
Anti-CD19 chimeric Antigen Receptor T Cells
8%
Breast
8%
Patients with Breast Cancer
7%
Glucose-regulated Protein 78 (GRP78)
7%
Treosulfan
7%
Human Epidermal Growth Factor Receptor 2-negative
7%
Ovarian Cancer
7%
Odds Ratio
7%
Medicine and Dentistry
Breast Cancer
100%
Diseases
33%
Overall Survival
27%
Neoplasm
22%
Allogeneic Stem Cell Transplantation
20%
Allogeneic Hematopoietic Stem Cell Transplantation
17%
BRCA1
17%
Acute Myeloid Leukemia
16%
Gamma Urogastrone
16%
Epidermal Growth Factor Receptor 2
15%
Hazard Ratio
14%
Recurrent Disease
12%
Fludarabine
12%
Estrogen Receptor
12%
Stem Cell Therapy
11%
Reduced Intensity Conditioning
11%
Chimeric Antigen Receptor T-Cell
11%
Progression Free Survival
10%
Graft Versus Host Reaction
10%
Non-Hodgkin Lymphoma
10%
Disease Free Survival
10%
Triple Negative Breast Cancer
9%
Germ Cell
9%
Cancer
9%
Hormone Receptor
9%
Chimeric Antigen Receptor T-Cell Immunotherapy
8%
Meta-Analysis
8%
Non-Relapse Mortality
8%
BRCA Mutation
8%
Trastuzumab
8%
Large-Cell Lymphoma
7%
Metastatic Breast Cancer
7%
Myelodysplastic Syndrome
7%
Cohort Analysis
7%
Radiation Therapy
7%
Cumulative Incidence
7%
Multivariate Analysis
7%
Malignant Neoplasm
7%
Ovarian Cancer
6%
Talazoparib
6%
Salvage Therapy
6%
Odds Ratio
6%
Conditioning
6%
Adverse Event
6%
Clinical Trial
6%
Acute Myelogenous Leukemia
6%
Recurrence Risk
6%
Prospective Study
6%
Acute Graft Versus Host Disease
6%
Cell Transplantation
6%